

## DAFTAR PUSTAKA

- Abbate, R., Cioni, G., Ricci, I., Miranda, M., Gori, A.M., 2012. Thrombosis and Acute coronary syndrome. *Thromb. Res.* 129, 235–240.
- Al-Bustan, S., El-Zawahri, M., Al-Azmi, D., Al-Bashir, A.-A., 2002. Allele frequencies and molecular genotyping of the ABO blood group system in a Kuwaiti population. *Int. J. Hematol.* 75, 147–153.
- Ambrose, J.A., Barua, R.S., 2004. The pathophysiology of cigarette smoking and cardiovascular diseaseAn update. *J. Am. Coll. Cardiol.* 43, 1731–1737.
- Auro, K., Alanne, M., Kristiansson, K., Silander, K., Kuulasmaa, K., Salomaa, V., Peltonen, L., Perola, M., 2007. Combined Effects of Thrombosis Pathway Gene Variants Predict Cardiovascular Events. *PLoS Genet* 3, e120.
- Authors/Task Force Members, Bassand, J.-P., Hamm, C.W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K.A.A., Hasdai, D., Ohman, E.M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S.D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J.L.Z., Silber, S., Funck-Brentano, C., Document Reviewers, Kristensen, S.D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A.F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J.E., Silber, S., Steg, P.G., Thygesen, K., Tubaro, M., Turpie, A.G.G., Verheugt, F., Windecker, S., 2007. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. *Eur. Heart J.* 28, 1598–1660.
- Barua, R.S., Ambrose, J.A., 2013. Mechanisms of Coronary Thrombosis in Cigarette Smoke Exposure. *Arterioscler. Thromb. Vasc. Biol.* 33, 1460–1467.
- Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., Margosan, D., Aftab, W., Ambrose, J.A., 2010a. Acute cigarette smoke exposure reduces clot lysis -- association between altered fibrin architecture and the response to t-PA. *Thromb. Res.* 126, 426–430.
- Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., Margosan, D., Ambrose, J.A., 2010b. Effects of Cigarette Smoke Exposure on Clot Dynamics and Fibrin Structure An Ex Vivo Investigation. *Arterioscler. Thromb. Vasc. Biol.* 30, 75–79.
- Bendetowicz, A.V., Wise, R.J., Gilbert, G.E., 1999. Collagen-bound von Willebrand Factor Has Reduced Affinity for Factor VIII. *J. Biol. Chem.* 274, 12300–12307.
- Benowitz, N.L., Fitzgerald, G.A., Wilson, M., Zhang, Q., 1993. Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking. *J. Am. Coll. Cardiol.* 22, 1159–1167.
- Bentzon, J.F., Otsuka, F., Virmani, R., Falk, E., 2014. Mechanisms of Plaque Formation and Rupture. *Circ. Res.* 114, 1852–1866.

- Bernardo, A., Ball, C., Nolasco, L., Moake, J.F., Dong, J., 2004. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. *Blood* 104, 100–106.
- Biancari, F., Satta, J., Pokela, R., Juvonen, T., 2002. ABO blood group distribution and severity of coronary artery disease among patients undergoing coronary artery bypass surgery in Northern Finland. *Thromb. Res.* 108, 195–196.
- Blache, D., 1995. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. *Am. J. Physiol. - Heart Circ. Physiol.* 268, H679–H685.
- Boffa, M.C., Karmochkine, M., 1998. Thrombomodulin: an overview and potential implications in vascular disorders. *Lupus* 7 Suppl 2, S120–125.
- Calnek, D.S., Grinnell, B.W., 1998. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. *Exp. Cell Res.* 238, 294–298.
- Chen, Y., Chen, C., Ke, X., Xiong, L., Shi, Y., Li, J., Tan, X., Ye, S., 2014. Analysis of Circulating Cholesterol Levels as a Mediator of an Association Between ABO Blood Group and Coronary Heart Disease. *Circ. Cardiovasc. Genet.* 7, 43–48.
- Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., Keech, A., Simes, J., Collins, R., 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 376, 1670–1681.
- Clark, P., Wu, O., 2011. ABO blood groups and thrombosis: a causal association, but is there value in screening?. *Future Cardiol.* 7, 191–201.
- Conway, E.M., Pollefeyt, S., Cornelissen, J., DeBaere, I., Steiner-Mosonyi, M., Weitz, J.I., Weiler-Guettler, H., Carmeliet, P., Collen, D., 1999. Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic *Domain* is not required for normal fetal development. *Blood* 93, 3442–3450.
- Conway, E.M., Wouwer, M.V. de, Pollefeyt, S., Jurk, K., Aken, H.V., Vriese, A.D., Weitz, J.I., Weiler, H., Hellings, P.W., Schaeffer, P., Herbert, J.-M., Collen, D., Theilmeier, G., 2002. The Lectin-like *Domain* of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor  $\kappa$ B and Mitogen-activated Protein Kinase Pathways. *J. Exp. Med.* 196, 565–577.
- Creager, M.A., Lüscher, T.F., Of, P. with the A., Cosentino, F., Beckman, J.A., 2003. Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I. *Circulation* 108, 1527–1532.
- Dahlbäck, B., Villoutreix, B.O., 2005. The anticoagulant protein C pathway. *FEBS Lett., Budapest Special Issue Proteins and Peptides* 579, 3310–3316.
- Delvaeye, M., Noris, M., De Vriese, A., Esmon, C.T., Esmon, N.L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., Zoja, C.,

- Remuzzi, G., Conway, E.M., 2009. Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome. *N. Engl. J. Med.* 361, 345–357.
- Esmon, C.T., 2003. The protein c pathway. *Chest* 124, 26S–32S.
- Fuentes-Prior, P., Iwanaga, Y., Huber, R., Pagila, R., Rumennik, G., Seto, M., Morser, J., Light, D.R., Bode, W., 2000. Structural basis for the anticoagulant activity of the thrombin–thrombomodulin complex. *Nature* 404, 518–525.
- Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., Shimomura, I., 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J. Clin. Invest.* 114, 1752–1761.
- Fusegawa, Y., Goto, S., Handa, S., Kawada, T., Ando, Y., 1999. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. *Thromb. Res.* 93, 271–278.
- Fuster, V., Moreno, P.R., Fayad, Z.A., Corti, R., Badimon, J.J., 2005. Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts. *J. Am. Coll. Cardiol.* 46, 937–954.
- Gallinaro, L., Cattini, M.G., Sztukowska, M., Padriani, R., Sartorello, F., Pontara, E., Bertomoro, A., Daidone, V., Pagnan, A., Casonato, A., 2008. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. *Blood* 111, 3540–3545.
- Gill, J.C., Endres-Brooks, J., Bauer, P.J., Marks, W.J., Montgomery, R.R., 1987. The effect of ABO blood group on the diagnosis of von Willebrand disease. *Blood* 69, 1691–1695.
- Hamada, H., Ishii, H., Sakyō, K., Horie, S., Nishiki, K., Kazama, M., 1995. The epidermal growth factor-like *Domain* of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. *Blood* 86, 225–233.
- Hansson, G.K., Jonasson, L., 2009. The Discovery of Cellular Immunity in the Atherosclerotic Plaque. *Arterioscler. Thromb. Vasc. Biol.* 29, 1714–1717.
- Harvey, P.J., Keightley, A.M., Lam, Y.M., Cameron, C., Lillicrap, D., 2000. A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels. *Br. J. Haematol.* 109, 349–353.
- He, M., Wolpin, B., Rexrode, K., Manson, J.E., Rimm, E., Hu, F.B., Qi, L., 2012. ABO Blood Group and Risk of Coronary Heart Disease in Two Prospective Cohort Studies. *Arterioscler. Thromb. Vasc. Biol.* 32, 2314–2320.
- Hotamisligil, G.S., Arner, P., Caro, J.F., Atkinson, R.L., Spiegelman, B.M., 1995. Increased adipose tissue expression of tumor necrosis factor- $\alpha$  in human obesity and insulin resistance. *J. Clin. Invest.* 95, 2409–2415.
- Huang, E.-W., Peng, L.-Y., Zheng, J.-X., Wang, D., Tan, X.-H., Yang, Z.-Y., Li, X.-M., Wu, Q.-P., Tang, S.-B., Luo, B., Quan, L., Liu, S.-P., Liu, X.-S., Li, Z.-H., Shi, H., Lv, G.-L., Zhao, J., Liu, C., Cheng, J.-D., 2016. Investigation of associations between ten polymorphisms and the risk of coronary artery disease in Southern Han Chinese. *J. Hum. Genet.* 61, 389–393.

- Hung, J., Lam, J.Y.T., Lacoste, L., Letchacovski, G., 1995. Cigarette Smoking Acutely Increases Platelet Thrombus Formation in Patients With Coronary Artery Disease Taking Aspirin. *Circulation* 92, 2432–2436.
- Jackman, R.W., Beeler, D.L., Fritze, L., Soff, G., Rosenberg, R.D., 1987. Human thrombomodulin gene is intron depleted: nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. *Proc. Natl. Acad. Sci.* 84, 6425–6429.
- Jenkins, P.V., O'Donnell, J.S., 2006. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. *Transfusion (Paris)* 46, 1836–1844.
- Jensen, T., Feldt-Rasmussen, B., Bjerre-Knudsen, J., Deckert, T., 1989. Features Of Endothelial Dysfunction In Early Diabetic Nephropathy. *The Lancet* 333, 461–463.
- Juhan-Vague, I., Thompson, S.G., Jespersen, J., 1993. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. *Arterioscler. Thromb. J. Vasc. Biol. Am. Heart Assoc.* 13, 1865–1873.
- Jukic, I., Bingulac-Popovic, J., Dogic, V., Hecimovic, A., Babic, I., Batarilo, I., Maglov, C., Sturm, D., 2013. Evaluation of ABO blood groups as a risk factor for myocardial infarction. *Blood Transfus.* 11, 464–465.
- Kiechl, S., Paré, G., Barbalic, M., Qi, L., Dupuis, J., Dehghan, A., Bis, J.C., Laxton, R.C., Xiao, Q., Bonora, E., Willeit, J., Xu, Q., Witteman, J.C.M., Chasman, D., Tracy, R.P., Ballantyne, C.M., Ridker, P.M., Benjamin, E.J., Ye, S., 2011. Association of Variation at the ABO Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and Soluble E-selectin Clinical Perspective. *Circ. Cardiovasc. Genet.* 4, 681–686.
- Koedam, J.A., Meijers, J.C., Sixma, J.J., Bouma, B.N., 1988. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.. *J. Clin. Invest.* 82, 1236–1243.
- Koutsis, A., Papapanagiotou, A., Papavassiliou, A.G., 2008. Thrombomodulin: From haemostasis to inflammation and tumourigenesis. *Int. J. Biochem. Cell Biol.* 40, 1669–1673.
- Koyama, T., Parkinson, J.F., Sié, P., Bang, N.U., Müller-Berghaus, G., Preissner, K.T., 1991. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. *Eur. J. Biochem. FEBS* 198, 563–570.
- Lee, H.-F., Lin, Y.-C., Lin, C.-P., Wang, C.-L., Chang, C.-J., Hsu, L.-A., 2012. Association of blood group A with coronary artery disease in young adults in Taiwan. *Intern. Med.* 51, 1815–1820.
- Leitinger, N., Schulman, I.G., 2013. Phenotypic Polarization of Macrophages in Atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 33, 1120–1126.
- Libby, P., 2001. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. *Circulation* 104, 365–372.
- Libby, P., Ridker, P.M., Hansson, G.K., 2009. Inflammation in Atherosclerosis: From Pathophysiology to Practice. *J. Am. Coll. Cardiol.* 54, 2129–2138.

- Libby, P., Ridker, P.M., Hansson, G.K., 2011. Progress and challenges in translating the biology of atherosclerosis. *Nature* 473, 317–325.
- Libby, P., Theroux, P., 2005. Pathophysiology of Coronary Artery Disease. *Circulation* 111, 3481–3488.
- Li, J.-J., Chen, J.-L., 2005. Inflammation may be a bridge connecting hypertension and atherosclerosis. *Med. Hypotheses* 64, 925–929.
- Li, Y.-H., Chen, J.-H., Tsai, W.-C., Chao, T.-H., Guo, H.-R., Tsai, L.-M., Wu, H.-L., Shi, G.-Y., 2002. Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. *Thromb. Haemost.* 87, 86–91.
- Li, Y.-H., Chen, J.-H., Wu, H.-L., Shi, G.-Y., Huang, H.-C., Chao, T.-H., Tsai, W.-C., Tsai, L.-M., Guo, H.-R., Wu, W.-S., others, 2000. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. *Am. J. Cardiol.* 85, 8–12.
- Lu, R.L., Esmon, N.L., Esmon, C.T., Johnson, A.E., 1989. The active site of the thrombin-thrombomodulin complex. A fluorescence energy transfer measurement of its distance above the membrane surface.. *J. Biol. Chem.* 264, 12956–12962.
- Massberg, S., Gawaz, M., Grüner, S., Schulte, V., Konrad, I., Zöhlhöfer, D., Heinzmann, U., Nieswandt, B., 2003. A Crucial Role of Glycoprotein VI for Platelet Recruitment to the Injured Arterial Wall In Vivo. *J. Exp. Med.* 197, 41–49.
- Meigs JB, Mittleman MA, Nathan DM, *et al*, 2000. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The framingham offspring study. *JAMA* 283, 221–228.
- Members, A.F., Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J.J., Borger, M.A., Brotons, C., Chew, D.P., Gencer, B., Hasenfuss, G., Kjeldsen, K., Lancellotti, P., Landmesser, U., Mehilli, J., Mukherjee, D., Storey, R.F., Windecker, S., 2015. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.*
- Minano, A., Ordonez, A., Espana, F., Gonzalez-Porrás, J.R., Lecumberri, R., Fontcuberta, J., Llamas, P., Marin, F., Estelles, A., Alberca, I., Vicente, V., Corral, J., 2008. ABO blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. *Haematologica* 93, 729–734.
- Miura, S., Li, C.Q., Cao, Z., Wang, H., Wardell, M.R., Sadler, J.E., 2000. Interaction of von Willebrand Factor Domain A1 with Platelet Glycoprotein Ib $\alpha$ -(1–289) Slow Intrinsic Binding Kinetics Mediate Rapid Platelet Adhesion. *J. Biol. Chem.* 275, 7539–7546.
- Mosnier, L.O., Zlokovic, B.V., Griffin, J.H., 2007. The cytoprotective protein C pathway. *Blood* 109, 3161–3172.
- Napoli, C., de Nigris, F., Williams-Ignarro, S., Pignalosa, O., Sica, V., Ignarro, L.J., 2006. Nitric oxide and atherosclerosis: An update. *Nitric Oxide* 15, 265–279.
- O'Donnell, J., Boulton, F.E., Manning, R.A., Laffan, M.A., 2002. Amount of H Antigen Expressed on Circulating von Willebrand Factor Is Modified by



- ABO Blood Group Genotype and Is a Major Determinant of Plasma von Willebrand Factor Antigen Levels. *Arterioscler. Thromb. Vasc. Biol.* 22, 335–341.
- O'Donnell, J., Laffan, M.A., 2001. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. *Transfus. Med.* 11, 343–351.
- Ohlin, A.K., Norlund, L., Marlar, R.A., 1997. Thrombomodulin gene variations and thromboembolic disease. *Thromb. Haemost.* 78, 396–400.
- Owen, W.G., Esmon, C.T., 1981. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. *J. Biol. Chem.* 256, 5532–5535.
- Paneni, F., Beckman, J.A., Creager, M.A., Cosentino, F., 2013. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. *Eur. Heart J.* 34, 2436–2443.
- Park, H.-Y., Nabika, T., Jang, Y., Kwon, H.M., Cho, S.Y., Masuda, J., 2002. Association of G-33A polymorphism in the thrombomodulin gene with myocardial infarction in Koreans. *Hypertens. Res.* 25, 389–394.
- Pourafkari, L., Ghaffari, S., Ahmadi, M., Tajlil, A., Nader, N.D., 2015. Association of ABO blood types with the risk of in-stent restenosis. *Perfusion* 0267659115573098.
- Reininger, A.J., Heijnen, H.F.G., Schumann, H., Specht, H.M., Schramm, W., Ruggeri, Z.M., 2006. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. *Blood* 107, 3537–3545.
- Rekam Medis RSUD dr. Saiful Anwar Malang, 2010. Data Rekam Medis RSUD dr. Saiful Anwar Malang. RSUD dr. Saiful Anwar Malang.
- Ruggeri, Z.M., 2000. Old concepts and new developments in the study of platelet aggregation. *J. Clin. Invest.* 105, 699–701.
- Ruggeri, Z.M., Orje, J.N., Habermann, R., Federici, A.B., Reininger, A.J., 2006. Activation-independent platelet adhesion and aggregation under elevated shear stress. *Blood* 108, 1903–1910.
- Sakakura, K., Nakano, M., Otsuka, F., Ladich, E., Kolodgie, F.D., Virmani, R., 2013. Pathophysiology of Atherosclerosis Plaque Progression. *Heart Lung Circ.* 22, 399–411.
- Savage, B., Saldívar, E., Ruggeri, Z.M., 1996. Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor. *Cell* 84, 289–297.
- Schenk-Braat, E.A., Morser, J., Rijken, D.C., 2001. Identification of the epidermal growth factor-like Domains of thrombomodulin essential for the acceleration of thrombin-mediated inactivation of single-chain urokinase-type plasminogen activator. *Eur. J. Biochem. FEBS* 268, 5562–5569.
- Séguin, C., Abid, M.R., Spokes, K.C., Aird, W.C., 2008. Thrombin downregulates thrombomodulin expression and activity in primary human endothelial cells. *Endothel. J. Endothel. Cell Res.* 15, 143–148.
- Sharif, S., Anwar, N., Farasat, T., Naz, S., 2014. ABO blood group frequency in Ischemic heart disease patients in Pakistani population. *Pak. J. Med. Sci.* 30, 593–595.
- Shi, C.-S., Shi, G.-Y., Hsiao, H.-M., Kao, Y.-C., Kuo, K.-L., Ma, C.-Y., Kuo, C.-H., Chang, B.-I., Chang, C.-F., Lin, C.-H., Wong, C.-H., Wu, H.-L., 2008.

- Lectin-like *Domain* of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. *Blood* 112, 3661–3670.
- Shi, J., Wang, J., Zheng, H., Ling, W., Joseph, J., Li, D., Mehta, J.L., Ponnappan, U., Lin, P., Fink, L.M., Hauer-Jensen, M., 2003. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. *Blood Coagul. Fibrinolysis Int. J. Haemost. Thromb.* 14, 575–585.
- Siedlecki, C.A., Lestini, B.J., Kottke-Marchant, K.K., Eppell, S.J., Wilson, D.L., Marchant, R.E., 1996. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. *Blood* 88, 2939–2950.
- Skålen, K., Gustafsson, M., Rydberg, E.K., Hultén, L.M., Wiklund, O., Innerarity, T.L., Borén, J., 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. *Nature* 417, 750–754.
- Sperry, J.L., Deming, C.B., Bian, C., Walinsky, P.L., Kass, D.A., Kolodgie, F.D., Virmani, R., Kim, A.Y., Rade, J.J., 2003. Wall tension is a potent negative regulator of in vivo thrombomodulin expression. *Circ. Res.* 92, 41–47.
- Spiel, A.O., Gilbert, J.C., Jilma, B., 2008. Von Willebrand Factor in Cardiovascular Disease Focus on Acute Coronary Syndromes. *Circulation* 117, 1449–1459.
- Stearns-Kurosawa, D.J., Kurosawa, S., Mollica, J.S., Ferrell, G.L., Esmon, C.T., 1996. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex.. *Proc. Natl. Acad. Sci. U. S. A.* 93, 10212–10216.
- Steinberg, D., 2009. The LDL modification hypothesis of atherogenesis: an update. *J. Lipid Res.* 50, S376–S381.
- Steinberg, D., Witztum, J.L., 2010. Oxidized Low-Density Lipoprotein and Atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 30, 2311–2316.
- Storry, J.R., Olsson, M.L., 2009. The ABO blood group system revisited: a review and update. *Immunohematol. Am. Red Cross* 25, 48–59.
- Suzuki, K., Kusumoto, H., Deyashiki, Y., Nishioka, J., Maruyama, I., Zushi, M., Kawahara, S., Honda, G., Yamamoto, S., Horiguchi, S., 1987. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation.. *EMBO J.* 6, 1891–1897.
- Tabas, I., Williams, K.J., Borén, J., 2007. Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis Update and Therapeutic Implications. *Circulation* 116, 1832–1844.
- Thompson, S.G., Kienast, J., Pyke, S.D., Haverkate, F., van de Loo, J.C., 1995. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. *N. Engl. J. Med.* 332, 635–641.
- Tohda, G., Oida, K., Okada, Y., Kosaka, S., Okada, E., Takahashi, S., Ishii, H., Miyamori, I., 1998. Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* 18, 1861–1869.

- Tolkatchev, D., Ng, A., Zhu, B., Ni, F., 2000. Identification of a thrombin-binding region in the sixth epidermal growth factor-like repeat of human thrombomodulin. *Biochemistry (Mosc.)* 39, 10365–10372.
- Tsiang, M., Lentz, S.R., Sadler, J.E., 1992. Functional *Domains* of membrane-bound human thrombomodulin. EGF-like *Domains* four to six and the serine/threonine-rich *Domain* are required for cofactor activity. *J. Biol. Chem.* 267, 6164–6170.
- Ueno, M., Ferreiro, J.L., Desai, B., Tomasello, S.D., Tello-Montoliu, A., Capodanno, D., Capranzano, P., Kodali, M., Dharmashankar, K., Charlton, R.K., Bass, T.A., Angiolillo, D.J., 2012. Cigarette Smoking Is Associated With a Dose-Response Effect in Clopidogrel-Treated Patients With Diabetes Mellitus and Coronary Artery Disease: Results of a Pharmacodynamic Study. *JACC Cardiovasc. Interv.* 5, 293–300.
- Van de Wouwer, M., Plaisance, S., De Vriese, A., Waelkens, E., Collen, D., Persson, J., Daha, M.R., Conway, E.M., 2006. The lectin-like *Domain* of thrombomodulin interferes with complement activation and protects against arthritis. *J. Thromb. Haemost. JTH* 4, 1813–1824.
- van Hinsbergh, V.W.M., 2012. Endothelium—role in regulation of coagulation and inflammation. *Semin. Immunopathol.* 34, 93–106.
- Vu, T.K., Hung, D.T., Wheaton, V.I., Coughlin, S.R., 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell* 64, 1057–1068.
- Wagner, D.D., 1990. Cell Biology of von Willebrand Factor. *Annu. Rev. Cell Biol.* 6, 217–242.
- Wang, H., Dong, P., 2015. Thrombomodulin –33G/A and Ala455Val polymorphisms are associated with the risk of coronary artery disease: a meta-analysis including 12 584 patients. *Coron. Artery Dis.* 26, 72–77.
- Wang, Y., Wang, L., Liu, X., Zhang, Y., Yu, L., Zhang, F., Liu, L., Cai, J., Yang, X., Wang, X., 2014. Genetic Variants Associated with Myocardial Infarction and the Risk Factors in Chinese Population. *PLOS ONE* 9, e86332.
- Weiler, H., Isermann, B.H., 2003. Thrombomodulin. *J. Thromb. Haemost.* 1, 1515–1524.
- Wiggins, K.L., Smith, N.L., Glazer, N.L., Rosendaal, F.R., Heckbert, S.R., Psaty, B.M., Rice, K.M., Lumley, T., 2009. ABO genotype and risk of thrombotic events and hemorrhagic stroke. *J. Thromb. Haemost.* 7, 263–269.
- Wood, M.J., Sampoli Benitez, B.A., Komives, E.A., 2000. Solution structure of the smallest cofactor-active fragment of thrombomodulin. *Nat. Struct. Biol.* 7, 200–204.
- World Health Organization, 2012a. WHO | The top 10 causes of death [WWW Document]. *WHO*. URL <http://www.who.int/mediacentre/factsheets/fs310/en/> (accessed 8.12.15).
- World Health Organization, 2012b. Indonesia: WHO Statistical Profile.
- Wouwer, M.V. de, Collen, D., Conway, E.M., 2004. Thrombomodulin-Protein C-EPCR System Integrated to Regulate Coagulation and Inflammation. *Arterioscler. Thromb. Vasc. Biol.* 24, 1374–1383.



- Wu, K.K., Aleksic, N., Ahn, C., Boerwinkle, E., Folsom, A.R., Juneja, H., Atherosclerosis Risk in Communities Study (ARIC) Investigators, 2001. Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. *Circulation* 103, 1386–1389.
- Wu, K.K., Thiagarajan, P., 1996. Role of endothelium in thrombosis and hemostasis. *Ann. Rev. Med.* 47, 315–331.
- Yamada, Y., Izawa, H., Ichihara, S., Takatsu, F., Ishihara, H., Hirayama, H., Sone, T., Tanaka, M., Yokota, M., 2002. Prediction of the Risk of Myocardial Infarction from Polymorphisms in Candidate Genes. *N. Engl. J. Med.* 347, 1916–1923.
- Zhang, S., Zhang, Z., Zhang, F., Wei, C., Bu, Y., Zheng, S., Su, D., 2014. Association between Thrombomodulin Polymorphisms and Coronary Artery Disease Risk: A Meta-Analysis. *Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.* 20, 1407–1414.
- Zhao, J., Zhou, X., Huang, J., Chen, J., Gu, D., 2005. Association study of the thrombomodulin -33G>A polymorphism with coronary artery disease and myocardial infarction in Chinese Han population. *Int. J. Cardiol.* 100, 383–388.
- Zhong, M., Zhang, H., Reilly, J.P., Chrisitie, J.D., Ishihara, M., Kumagai, T., Azadi, P., Reilly, M.P., 2015. ABO Blood Group as a Model for Platelet Glycan Modification in Arterial Thrombosis. *Arterioscler. Thromb. Vasc. Biol.* 35, 1570–1578.